Connection
Wells Messersmith to Early Termination of Clinical Trials
This is a "connection" page, showing publications Wells Messersmith has written about Early Termination of Clinical Trials.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.027 |
|
|
|
-
Hochster HS, Uboha N, Messersmith W, Gold PJ, ONeil BH, Cohen D, Denlinger C, Cohen S, Leichman CG, Leichman L, Lenz HJ. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother Pharmacol. 2015 Jan; 75(1):17-23.
Score: 0.027